靶向前列腺癌中的雄激素信号轴
本文综述雄激素受体(AR)及AR驱动的转录程序在前列腺癌病理生理中的核心作用,回顾AR信号依赖的耐药机制及下一代AR靶向治疗在去势抵抗性和去势敏感性前列腺癌中的临床验证,并探讨AR靶向治疗的新前沿。
要点
- AR及AR驱动的转录程序是前列腺癌病理生理的核心。
- 下一代AR靶向治疗对去势抵抗性前列腺癌有效,验证了持续依赖AR信号。
- 转移性前列腺癌仍大多不可治愈,需理解肿瘤逃避AR靶向治疗的机制。
核心结论
- 转移性前列腺癌很大程度上仍不可治愈,凸显需更好理解肿瘤逃避AR靶向治疗的多样机制以启发新治疗途径。
研究设计与样本
- 综述,回顾AR信号概念、AR信号依赖的耐药机制及前列腺癌AR靶向的新前沿。
主要发现
- AR激活及AR驱动的转录程序是前列腺癌病理生理的核心。
- 尽管靶向AR的转化研究成功,治疗耐药常因雄激素信号轴的分子改变而发生。
- 下一代AR靶向治疗对去势抵抗性前列腺癌的疗效为持续依赖AR信号提供了关键临床验证,并为去势抵抗性和去势敏感性患者引入一系列新治疗选择。
局限性
- 转移性前列腺癌很大程度上仍不可治愈,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to the pathophysiology of prostate cancer. Despite successful translational efforts in targeting AR, therapeutic resistance often occurs as a result of molecular alterations in the androgen signaling axis. The efficacy of next-generation AR-directed therapies for castration-resistant prostate cancer has provided crucial clinical validation for the continued dependence on AR signaling and introduced a range of new treatment options for men with both castration-resistant and castration-sensitive disease. Despite this, however, metastatic prostate cancer largely remains an incurable disease, highlighting the need to better understand the diverse mechanisms by which tumors thwart AR-directed therapies, which may inform new therapeutic avenues. In this review, we revisit concepts in AR signaling and current understandings of AR signaling-dependent resistance mechanisms as well as the next frontier of AR targeting in prostate cancer.
引用
- Dai C, Dehm SM, Sharifi N, et al. Targeting the Androgen Signaling Axis in Prostate Cancer. J Clin Oncol. 2023. PMID: 37429011. doi:10.1200/JCO.23.00433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。